Our discovery strategy provides the basis for development of first-in-class preclinical monoclonal antibodies and oligonucleotide candidates that have novel therapeutic potential in orphan and rare diseases.

Internal innovation at THOR therapeutics is enhanced by key collaborators with global expertise, to ensure that our projects are pursued with in-depth understanding of the target biology necessary to develop novel efficacious treatments to tackle unmet needs.